Advertise on podcast: Crohn’s & Colitis Foundation Perspectives

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Peter D. Higgins, MDm PhD What were some of the key takeaways from the 2022 Crohn's & Colitis Congress, and what's in store for next year’s conference? Hear from the incoming 2023 Congress Chair Dr. Peter D. Higgins.

Host: Jennifer Caudle, DO Guest: Ashish S. Patel, MD Treating IBD in our pediatric patients can be challenging, which is why creating a strong partnership between care teams and patients’ families is key. Fortunately, that was a central focus of the 2022 Crohn's & Colitis Congress, so to catch the latest updates and strategies for improving IBD care for pediatric patients, tune in to hear Dr. Jennifer Caudle speak with Dr. Ashish Patel.

Host: Jennifer Caudle, DO Guest: Alan C. Moss, MD When patients with moderate ulcerative colitis fail first-line therapy, it's important to know what to do next. And speaking with your patients about their risks and preferences is key. Join us as Dr. Alan Moss shares highlights from his presentation at the 2022 Crohn's & Colitis Congress on treatment considerations for patients with moderate ulcerative colitis.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Caren Heller, MD, MBA For patients living with IBD, paying special attention to their nutrition is paramount. So which is more effective for IBD patients with mild-to-moderate symptoms: a Mediterranean style diet or the Special Carbohydrate diet? That’s what the Diets to Induce Remission in Crohn's Disease (DINE-CD) study sought to find out, and now the results are in. Join Dr. Peter Buch as he explores the study's key findings with Dr. Caren Heller, Chief Scientific Officer at the Crohn's and Colitis Foundation.

Guest: Jordan E. Axelrad, MD, MPH Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE) Mark T Osterman, Frank I Scott, Franz F Fogt, Erin D Gilroy, Susan Parrott, Joseph Galanko, Raymond Cross, Alan Moss, Hans H Herfarth, Peter D R Higgins Abstract Objective: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse. Design: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley …

Guest: Xiaohong Wang, MD, PhD Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study Walter Reinisch, Remo Panaccione, Peter Bossuyt, Filip Baert, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, William J Sandborn, Stefan Schreiber, Sofie Berg, Qian Zhou, Kristina Kligys, Ezequiel Neimark, Ahmed A Suleiman, Geert D'Haens, Jean-Frederic Colombel Background: CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points. Methods: The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS) 4 and no deep ulcers 48 weeks after randomization was evaluated according to CRP 5 mg/L or ≥5 mg/L and FC 250 μg/g or ≥250 μg/g. Subgroup analyses were performed according to disease location, and sensitivity analyses were conducted in patients with elevated CRP and/or FC at baseline. The association between endoscopic end points and biomarker cutoffs was performed using …

Guest: Tina Aswani Omprakash Wellness includes many different aspects, but what about mental health and the stressors of life that affect IBD patients? Joining Dr. Charles Turck to share key takeaways from a session at the 2021 Crohn’s and Colitis Congress called “Holistic View of IBD Diet Disparities and Well-Being” is Tina Aswani Omprakash, patient advocate and co-moderator of the session.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Siddharth Singh, MD Dr. Charles Turck is joined by Dr. Siddharth Singh from the University of California, San Diego, to discuss emerging therapies for inflammatory bowel disease, or IBD, and share some highlights from the session “The Future of IBD Treatments” from Crohn’s & Colitis Congress 2021.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Frank Scott Dr. Charles Turck is joined by Dr. Frank Scott from the University of Colorado School of Medicine to share some highlights from his session, “Challenges and New Approaches to Managing IBD in the COVID-19 Era,” at Crohn’s & Colitis Congress 2021.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stephen Hanauer, MD Dr. Turck joins Dr. Stephen Hanauer of Northwestern University to discuss some of the highlights from his upcoming presentation at the 2021 Crohn’s & Colitis Congress, a Partnership of the Crohn’s and Colitis Foundation and the American Gastroenterological Association.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael D. Kappelman, MD, MPH Pediatric care has evolved amid the COVID-19 pandemic. And when it comes to treating inflammatory bowel disorder, or IBD, gastroenterologists are faced with a unique set of challenges. Join us as Dr. Kappelman shares highlights of his presentation at the 2021 Crohn’s & Colitis Congress on what needs to be acknowledged while treating children with IBD during the COVID-19 pandemic.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maria M. Oliva-Hemker, MD With current treatment approaches in mind, how do immunomodulators fit into the therapeutic landscape for inflammatory bowel disorders, or IBD? In preparation for the 2021 Crohn’s & Colitis Congress, Dr. Charles Turck speaks with Dr. Maria Oliva-Hemker from Johns Hopkins University School of Medicine about her presentation at the event.